Phase 1 N=234 A Study of Sensitizing Potential of Diacerein 1% Ointment in Healthy Subjects
Healthy
Primary: Observed Sensitization — 0; 0; 0 Participants with Observed Sensitization
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=61 OxyNorm® Capsules (Immediate-Release) Pharmacokinetic (PK) Study
Pain
Primary: AUC0-t and AUC0-∞ for Participants Who Received a Single Dose — 57.03; 102.10; 205.89; 58.38 ng*hr*ml
Phase 1 N=16 GSK3640254 First Time in Human (FTIH) Study in Healthy Volunteers
Infection, Human Immunodeficiency Virus · HIV Infections
Primary: Part 1:Number of Participants With Adverse Events (AEs) and Serious AEs (SAEs) — 3; 2; 4; 3 Participants
Phase 1 N=11 Safety, Tolerability, and Pharmacokinetics of KBP-5074 Following Oral Administration in Chronic Kidney Disease
Chronic Kidney Disease
Primary: Number of Participants With Treatment-related Adverse Events — 0 Participants
Phase 1 N=12 A Study in Opioid-Experienced, Non-Dependent Recreational Drug Users to Determine the Abuse Potential and Safety of CL-108 Tablets Administered Via the Oral Route
Pain · Nausea · Vomiting
Primary: Subjective Effects: Maximum Effect (Emax) and Minimum Effect (Emin) of High Visual Analog Scale (VAS) in Dose Selection Phase — 85.0; 42.0; 75.5; 94.0 units on a scale
Phase 1 N=32 A Study of Single or Repeated Doses of Glucagon in Participants With Diabetes
Diabetes Mellitus, Type 1 · Diabetes Mellitus, Type 2
Primary: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to T(AUC[0-tlast]) of Baseline-Adjusted Glucagon — 2470; 4100; 4640; 3610…
Phase 1 N=19 Pharmacokinetics of Bictegravir in Adults With Normal and Impaired Renal Function
HIV
Primary: Pharmacokinetic (PK) Parameter: AUCinf of Bictegravir (Total) — 138169.7; 170105.6 h*ng/mL
Phase 1 N=30 Hyaluronidase Effect on Infusion Set Life
Type 1 Diabetes Mellitus
Primary: Duration of Insulin Infusion Set Wear as a Measure of the Effect of Hyaluronidase Treatment — 5.7; 5.4 Days of wear
Phase 1 N=33 Evaluation of a New Anti-cancer Immunotherapy in Patients With Non-operable and Progressing Metastatic Cutaneous Melanoma
Melanoma
Primary: Number of Patients With Severe Toxicities During the Study Treatment Period — 0 Participants
Phase 1 N=30 Study of T Cells Targeting B-Cell Maturation Antigen for Previously Treated Multiple Myeloma
Myeloma, Plasma-Cell · Myeloma-Multiple
Primary: Number of Participants With Dose Limiting Toxicities — 0; 0; 0; 4 Participants
Phase 1 N=44 Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Pembrolizumab (MK-3475) in Chinese Participants With Non-Small-Cell Lung Cancer (MK-3475-032/KEYNOTE-032)
Non-Small-Cell Lung Cancer
Primary: Number of Participants Who Experienced an Adverse Event (AE) — 14; 13; 14 Participants
Phase 1 N=15 Study of NGR-hTNF in Combination With Doxorubicin in Solid Tumors
Cancer
Primary: Number of Adverse Events From Escalating Doses of NGR-hTNF in Combination With a Fixed Dose of Doxorubicin — 59; 142; 67; 101 Adverse event
Phase 1 N=24 Daylight Photodynamic Therapy for Actinic Keratosis
Actinic Keratoses
Primary: Change in Treatment Symptoms — 3.9; 0.5; 0.37 score on a scale
Phase 1 N=142 Comparative, Pharmacokinetic and Pharmacodynamic Study of Subcutaneous Injections of INTP5 of Intas Pharmaceuticals Ltd., India Against Neulasta of Amgen Inc., USA in Healthy, Adult Human Subjects.
Pharmacokinetic Bioequivalence Study in Human Healthy Volunteers
Primary: Pharmacokinetic (PK) Endpoints: Pegfilgrastim C[Max] — 474.269; 425.578 ng/mL
Phase 1 N=35 Pharmacokinetics and Pharmacodynamics of RPH-104 in Healthy Subjects
Healthy
Primary: Adverse Events — 0; 0 participants